Status and phase
Conditions
Treatments
About
The purpose of the study is to evaluate the efficacy and safety of autologous CD34+ cells that stably express multiplexed shRNA to treat HIV infection.
Full description
CD34+ cells will be isolated from mobilized PBMC of HIV patients. The cells will be lentivirally transduced with multiplexed shRNAs in the same vector that target CCR5 and HIV genome. Such modified cells will be infused back to the patients who have received bulsufan preconditioning before infusion. The patients will then be evaluated for efficacy and safety.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
6 participants in 3 patient groups
Loading...
Central trial contact
Hongzhou Lu, M.D., Ph.D; Li Liu, M.D., Ph.D
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal